Maze Therapeutics Exchanges 2.78 Million Shares for Pre-Funded Warrants

Maze Therapeutics agreed with Frazier Life Sciences funds to exchange 2,776,007 common shares for pre-funded warrants exercisable at $0.001, subject to a 9.99% ownership blocker. The reported post-exchange share figure is truncated in the source.